Key regions: France, Europe, United Kingdom, Brazil, India
The demand for oncology drugs in Nordics is increasing at a steady pace, driven by various factors such as the rising prevalence of cancer, increasing healthcare expenditure, and the presence of key market players.
Customer preferences: Patients in Nordics prefer personalized and targeted therapies for cancer treatment, which has led to the development of innovative drugs that target specific genetic mutations and pathways. Additionally, patients also prefer drugs with minimal side effects and a high success rate.
Trends in the market: The oncology drugs market in Nordics is witnessing a shift towards immunotherapy drugs, which stimulate the body's immune system to fight cancer cells. This trend is driven by the high success rate of immunotherapy drugs in treating various types of cancer, including melanoma and lung cancer. Another trend in the market is the increasing focus on precision medicine, which involves the use of genetic testing to identify the specific mutations driving a patient's cancer and selecting the most effective treatment accordingly.
Local special circumstances: The Nordics region is characterized by a strong healthcare system that provides universal access to healthcare services. This has led to an increased demand for oncology drugs, as more patients are able to access cancer treatment. Additionally, the region has a high prevalence of certain types of cancer, such as lung cancer and breast cancer, which has further fueled the demand for oncology drugs.
Underlying macroeconomic factors: The oncology drugs market in Nordics is also influenced by various macroeconomic factors, such as increasing healthcare expenditure and the presence of key market players. The Nordics region has a high healthcare expenditure per capita, which has enabled the development and adoption of innovative drugs. Additionally, the presence of key market players such as AstraZeneca and Novartis has contributed to the growth of the oncology drugs market in the region.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
